Guardant Health, Inc. (GH)

NASDAQ: GH · Real-Time Price · USD

92.23

-1.67 (-1.78%)

At close: Mar 2, 2026, 4:00 PM EST

90.00

-2.23 (-2.42%)

Pre-market: Mar 3, 2026, 8:47 AM EST

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States Revenue	923.28M	697.16M
United States Revenue Growth	32.43%	32.41%
International Revenue	58.74M	41.85M
International Revenue Growth	40.35%	11.84%
Revenue (Total)	982.02M	739.02M
Revenue (Total) Growth	32.88%	31.04%

Revenue Breakdown

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Oncology Revenue	683.60M	542.83M
Oncology Revenue Growth	25.93%	34.40%
Biopharma and Data Revenue	210.13M	177.58M
Biopharma and Data Revenue Growth	18.33%	30.24%
Screening Revenue	79.73M	5.12M
Screening Revenue Growth	1456.05%	-
Licensing and Other Revenue	8.56M	13.49M
Licensing and Other Revenue Growth	-36.51%	-43.15%
Revenue (Total)	982.02M	739.02M
Revenue (Total) Growth	32.88%	31.04%

Revenue Breakdown 2

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Precision Oncology Testing Revenue	-	687.94M
Precision Oncology Testing Revenue Growth	-	33.77%
Development Services and Other Revenue	-	51.08M
Development Services and Other Revenue Growth	-	2.78%
Revenue (Total)	982.02M	739.02M
Revenue (Total) Growth	32.88%	31.04%

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Precision Oncology Testing Gross Profit	-	427.36M
Precision Oncology Testing Gross Profit Growth	-	38.43%
Development Services and Other Gross Profit	-	21.86M
Development Services and Other Gross Profit Growth	-	-22.41%
Gross Profit (Total)	633.01M	449.22M
Gross Profit (Total) Growth	40.91%	33.34%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Clinical Test Sales Volume	276.00K	206.70K
Clinical Test Sales Volume Growth	33.53%	19.55%
Biopharmaceutical Test Sales Volume	-	40.50K
Biopharmaceutical Test Sales Volume Growth	-	35.45%

Updated Feb 19, 2026. Data Source: Fiscal.ai.